{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:37:01Z","timestamp":1791423421195,"version":"4.3.3"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme Corp"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40261-020-00934-2","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T14:02:47Z","timestamp":1597932167000},"page":"927-946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug\u2013Drug Interactions"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8746-1832","authenticated-orcid":false,"given":"Sauzanne","family":"Khalilieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3099-4440","authenticated-orcid":false,"given":"Ka Lai","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Aubrey","family":"Stoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Wenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"934_CR1","unstructured":"UNAIDS. Global HIV & AIDS statistics-2019 fact sheet. 2019. http:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed 19 Aug 2019."},{"key":"934_CR2","unstructured":"European AIDS Clinical Society. European guidelines for treatment of HIV-positive adults in Europe, version 9.1. http:\/\/www.eacsociety.org\/files\/2018_guidelines-9.1-english.pdf. Accessed 14 May 2019."},{"key":"934_CR3","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. 2018. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf. Accessed 19 Aug 2019."},{"key":"934_CR4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/ciy540","volume":"68","author":"C Orkin","year":"2019","unstructured":"Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, et al. Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial. Clin Infect Dis. 2019;68:535\u201344.","journal-title":"Clin Infect Dis"},{"key":"934_CR5","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","volume":"5","author":"JM Molina","year":"2018","unstructured":"Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e211\u201320.","journal-title":"Lancet HIV."},{"key":"934_CR6","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1128\/AAC.02650-15","volume":"60","author":"M Feng","year":"2016","unstructured":"Feng M, Sachs NA, Xu M, Grobler J, Blair W, Hazuda DJ, et al. Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob Agents Chemother. 2016;60:2241\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"934_CR7","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/AAC.04201-14","volume":"59","author":"M Feng","year":"2015","unstructured":"Feng M, Wang D, Grobler JA, Hazuda DJ, Miller MD, Lai M-T. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother. 2015;59:590\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"934_CR8","unstructured":"Merck Sharp & Dohme Corp. PIFELTRO\u2122 (doravirine) Prescribing Information. Merck & Co., Inc., Whitehouse Station, NJ, USA. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_pi.pdf. Accessed 14 May 2020."},{"key":"934_CR9","unstructured":"Merck Sharp & Dohme Corp. DELSTRIGO\u2122 (doravirine, lamivudine, and tenofovir disoproxil fumarate) Prescribing Information. Merck & Co., Inc., Whitehouse Station, NJ, USA. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_pi.pdf. Accessed 14 May 2020."},{"key":"934_CR10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/00498254.2018.1451667","volume":"49","author":"RI Sanchez","year":"2019","unstructured":"Sanchez RI, Fillgrove KL, Yee KL, Liang Y, Lu B, Tatavarti A, et al. Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica. 2019;49:422\u201332.","journal-title":"Xenobiotica"},{"key":"934_CR11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3851\/IMP2920","volume":"20","author":"MS Anderson","year":"2015","unstructured":"Anderson MS, Gilmartin J, Cilissen C, De Lepeleire I, van Bortel L, Dockendorf MF, et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2015;20:397\u2013405.","journal-title":"Antivir Ther."},{"issue":"6","key":"934_CR12","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/jac\/dkaa038","volume":"75","author":"X Wang","year":"2020","unstructured":"Wang X, Milinkovic A, Pereira B, Moyle G, Fedele S, Thomas L, et al. Pharmacokinetics of once-daily doravirine over 72 h following drug cessation. J Antimicrob Chemother. 2020;75(6):1658\u201360.","journal-title":"J Antimicrob Chemother."},{"key":"934_CR13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/QAD.0000000000000876","volume":"30","author":"D Sch\u00fcrmann","year":"2016","unstructured":"Sch\u00fcrmann D, Sobotha C, Gilmartin J, Robberechts M, De Lepeleire I, Yee KL, et al. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals. AIDS. 2016;30:57\u201363.","journal-title":"AIDS."},{"key":"934_CR14","first-page":"e02502","volume":"63","author":"KL Yee","year":"2019","unstructured":"Yee KL, Ouerdani A, Claussen A, de Greef R, Wenning L. Population pharmacokinetics of doravirine and exposure-response in individuals with HIV-1. Antimicrob Agents Chemother. 2019;63:e02502\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"934_CR15","doi-asserted-by":"crossref","first-page":"e01757-16","DOI":"10.1128\/AAC.01757-16","volume":"61","author":"KL Yee","year":"2017","unstructured":"Yee KL, Sanchez RI, Auger P, Liu R, Fan L, Triantafyllou I, et al. Evaluation of doravirine pharmacokinetics when switching from efavirenz to doravirine in healthy subjects. Antimicrob Agents Chemother. 2017;61:e01757-16.","journal-title":"Antimicrob Agents Chemother."},{"key":"934_CR16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/cts.12395","volume":"9","author":"Y Xu","year":"2016","unstructured":"Xu Y, Li YF, Zhang D, Dockendorf M, Tetteh E, Rizk ML, et al. Characterizing class-specific exposure-viral load suppression response of HIV antiretrovirals using a model-based meta-analysis. Clin Transl Sci. 2016;9:192\u2013200.","journal-title":"Clin Transl Sci."},{"key":"934_CR17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3851\/IMP3323","volume":"24","author":"JM Gatell","year":"2019","unstructured":"Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Arasteh K, Hoffmann C, et al. Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial. Antivir Ther. 2019;24:425\u201335.","journal-title":"Antivir Ther."},{"key":"934_CR18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.bmcl.2013.12.070","volume":"24","author":"B Cote","year":"2014","unstructured":"Cote B, Burch JD, Asante-Appiah E, Bayly C, Bedard L, Blouin M, et al. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg Med Chem Lett. 2014;24:917\u201322.","journal-title":"Bioorg Med Chem Lett"},{"key":"934_CR19","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1128\/AAC.02403-13","volume":"58","author":"MT Lai","year":"2014","unstructured":"Lai MT, Feng M, Falgueyret JP, Tawa P, Witmer M, DiStefano D, et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2014;58:1652\u201363.","journal-title":"Antimicrob Agents Chemother"},{"key":"934_CR20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40262-016-0458-4","volume":"56","author":"MS Anderson","year":"2017","unstructured":"Anderson MS, Khalilieh S, Yee KL, Liu R, Fan L, Rizk ML, et al. A two-way steady-state pharmacokinetic interaction study of doravirine (MK-1439) and dolutegravir. Clin Pharmacokinet. 2017;56:661\u20139.","journal-title":"Clin Pharmacokinet"},{"key":"934_CR21","doi-asserted-by":"crossref","first-page":"e01364-16","DOI":"10.1128\/AAC.01364-16","volume":"61","author":"S Khalilieh","year":"2017","unstructured":"Khalilieh S, Yee KL, Sanchez RI, Triantafyllou I, Fan L, Maklad N, et al. Results of a doravirine-atorvastatin drug-drug interaction study. Antimicrob Agents Chemother. 2017;61:e01364-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"934_CR22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3851\/IMP3142","volume":"22","author":"MO Behm","year":"2017","unstructured":"Behm MO, Yee KL, Fan L, Fackler P. Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects. Antivir Ther. 2017;22:337\u201344.","journal-title":"Antivir Ther."},{"key":"934_CR23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40261-017-0512-5","volume":"37","author":"MO Behm","year":"2017","unstructured":"Behm MO, Yee KL, Liu R, Levine V, Panebianco D, Fackler P. The effect of food on doravirine bioavailability: results from two pharmacokinetic studies in healthy subjects. Clin Drug Investig. 2017;37:571\u20139.","journal-title":"Clin Drug Investig."},{"key":"934_CR24","doi-asserted-by":"crossref","first-page":"e00326-18","DOI":"10.1128\/AAC.00326-18","volume":"62","author":"W Ankrom","year":"2018","unstructured":"Ankrom W, Yee KL, Sanchez RI, Adedoyin A, Fan L, Marbury T, et al. Severe renal impairment has minimal impact on doravirine pharmacokinetics. Antimicrob Agents Chemother. 2018;62:e00326-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"934_CR25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/jcph.857","volume":"57","author":"S Khalilieh","year":"2017","unstructured":"Khalilieh S, Yee KL, Liu R, Fan L, Sanchez RI, Auger P, et al. Moderate hepatic impairment does not affect doravirine pharmacokinetics. J Clin Pharmacol. 2017;57:777\u201383.","journal-title":"J Clin Pharmacol"},{"key":"934_CR26","doi-asserted-by":"crossref","first-page":"e02016-18","DOI":"10.1128\/AAC.02016-18","volume":"63","author":"SG Khalilieh","year":"2019","unstructured":"Khalilieh SG, Yee KL, Sanchez RI, Fan L, Anderson MS, Sura M, et al. Doravirine and the potential for CYP3A-mediated drug-drug interactions. Antimicrob Agents Chemother. 2019;63:e02016-18.","journal-title":"Antimicrob Agents Chemother."},{"key":"934_CR27","doi-asserted-by":"crossref","first-page":"e02491-18","DOI":"10.1128\/AAC.02491-18","volume":"63","author":"W Ankrom","year":"2019","unstructured":"Ankrom W, Sanchez RI, Yee KL, Fan L, Mitra P, Wolford D, et al. Investigation of pharmacokinetic interactions between doravirine and elbasvir\/grazoprevir and ledipasvir\/sofosbuvir. Antimicrob Agents Chemother. 2019;63:e02491-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"934_CR28","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/jcph.1399","volume":"59","author":"SG Khalilieh","year":"2019","unstructured":"Khalilieh SG, Yee KL, Sanchez RI, Fan L, Vaynshteyn K, Deschamps K, et al. A study to evaluate doravirine pharmacokinetics when coadministered with acid-reducing agents. J Clin Pharmacol. 2019;59:1093\u20138.","journal-title":"J Clin Pharmacol"},{"key":"934_CR29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cpdd.685","volume":"9","author":"RI Sanchez","year":"2020","unstructured":"Sanchez RI, Yee KL, Fan L, Cislak D, Martell M, Jordan HR, et al. Evaluation of the pharmacokinetics of metformin following coadministration with doravirine in healthy volunteers. Clin Pharmacol Drug Dev. 2020;9:107\u201314.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"934_CR30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/cpdd.699","volume":"9","author":"S Khalilieh","year":"2019","unstructured":"Khalilieh S, Yee KL, Sanchez RI, Vaynshteyn K, Fan L, Searle S, et al. Evaluation of the pharmacokinetic interaction between doravirine and methadone. Clin Pharmacol Drug Dev. 2019;9:151\u201361.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"934_CR31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3851\/IMP3324","volume":"24","author":"MS Anderson","year":"2019","unstructured":"Anderson MS, Gilmartin J, Fan L, Yee KL, Kraft WK, Triantafyllou I, et al. No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate co-administration. Antivir Ther. 2019;24:443\u201350.","journal-title":"Antivir Ther."},{"key":"934_CR32","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40261-017-0552-x","volume":"37","author":"SG Khalilieh","year":"2017","unstructured":"Khalilieh SG, Yee KL, Fan L, Liu R, Heber W, Dunzo E, et al. A randomized trial to assess the effect of doravirine on the QTc interval using a single supratherapeutic dose in healthy adult volunteers. Clin Drug Investig. 2017;37:975\u201384.","journal-title":"Clin Drug Investig."},{"key":"934_CR33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6\u201314.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 2","key":"934_CR34","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1097\/QAD.0000000000001374","volume":"31","author":"CA Sabin","year":"2017","unstructured":"Sabin CA, Reiss P. Epidemiology of ageing with HIV: what can we learn from cohorts? AIDS. 2017;31(Suppl 2):S121\u20138.","journal-title":"AIDS."},{"key":"934_CR35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/QAD.0000000000002372","volume":"34","author":"P Courlet","year":"2020","unstructured":"Courlet P, Stader F, Guidi M, Alves Saldanha S, Stoeckle M, Cavassini M, et al. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. Aids. 2020;34:103\u20138.","journal-title":"Aids."},{"key":"934_CR36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","volume":"48","author":"OP Soldin","year":"2009","unstructured":"Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48:143\u201357.","journal-title":"Clin Pharmacokinet"},{"key":"934_CR37","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1124\/dmd.109.031328","volume":"38","author":"Z-Y Hu","year":"2010","unstructured":"Hu Z-Y, Zhao Y-S. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis. Drug Metab Dispos. 2010;38:817\u201323.","journal-title":"Drug Metab Dispos"},{"key":"934_CR38","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/infdis\/jix238","volume":"216","author":"J Gallant","year":"2017","unstructured":"Gallant J, Hsue PY, Shreay S, Meyer N. Comorbidities among US patients with prevalent HIV infection\u2014a trend analysis. J Infect Dis. 2017;216:1525\u201333.","journal-title":"J Infect Dis"},{"key":"934_CR39","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cgh.2010.08.024","volume":"8","author":"JC Price","year":"2010","unstructured":"Price JC, Thio CL. Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol. 2010;8:1002\u201312.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"934_CR40","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147\u201361.","journal-title":"Eur J Clin Pharmacol"},{"key":"934_CR41","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.5414\/CNP83S032","volume":"83","author":"S Naicker","year":"2015","unstructured":"Naicker S, Rahmanian S, Kopp JB. HIV and chronic kidney disease. Clin Nephrol. 2015;83:S32\u20138.","journal-title":"Clin Nephrol"},{"key":"934_CR42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.ackd.2015.10.002","volume":"23","author":"MA Ladda","year":"2016","unstructured":"Ladda MA, Goralski KB. The effects of CKD on cytochrome P450-mediated drug metabolism. Adv Chronic Kidney Dis. 2016;23:67\u201375.","journal-title":"Adv Chronic Kidney Dis."},{"key":"934_CR43","unstructured":"Food and Drug Administration (FDA). Full prescribing information: INTELENCE\u2122 (etravirine). 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022187s023lbl.pdf. Accessed 29 Apr 2019."},{"key":"934_CR44","unstructured":"Janssen Therapeutics. EDURANT\u00ae (rilpivirine) prescribing information. 2018. http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/EDURANT-pi.pdf. Accessed 23 May 2018."},{"key":"934_CR45","doi-asserted-by":"crossref","first-page":"e02492-18","DOI":"10.1128\/AAC.02492-18","volume":"63","author":"K Bleasby","year":"2019","unstructured":"Bleasby K, Fillgrove KL, Houle R, Lu B, Palamanda J, Newton DJ, et al. In vitro evaluation of the drug interaction potential of doravirine. Antimicrob Agents Chemother. 2019;63:e02492-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"934_CR46","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1177\/1060028013504075","volume":"47","author":"A Tseng","year":"2013","unstructured":"Tseng A, Szadkowski L, Walmsley S, Salit I, Raboud J. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother. 2013;47:1429\u201339.","journal-title":"Ann Pharmacother"},{"key":"934_CR47","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","volume":"16","author":"L Platt","year":"2016","unstructured":"Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16:797\u2013808.","journal-title":"Lancet Infect Dis."},{"key":"934_CR48","unstructured":"GlaxoSmithKline\/ViiV Healthcare. EPIVIR (lamivudine) prescribing information. 2019. https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Epivir\/pdf\/EPIVIR-PI-PIL.PDF. Accessed 19 Aug 2019."},{"key":"934_CR49","unstructured":"Gilead Sciences, Inc. VIREAD\u00ae (tenofovir disoproxil fumarate) Prescribing Information. 2018. http:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liver-disease\/viread\/viread_pi.pdf. Accessed 19 Aug 2019."},{"key":"934_CR50","unstructured":"Gilead Sciences, Inc. VEMLIDY\u00ae (tenofovir alafenamide) prescribing information. 2018. https:\/\/www.gilead.com\/~\/media\/files\/pdfs\/medicines\/liver-disease\/vemlidy\/vemlidy_pi.pdf. Accessed 22 Oct 2018."},{"key":"934_CR51","unstructured":"Bristol-Myers Squibb Co. Sustiva\u00ae (efavirenz) prescribing information. 2019. https:\/\/packageinserts.bms.com\/pi\/pi_sustiva.pdf. Accessed 26 Feb 2020."},{"key":"934_CR52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mcp.2002.124519","volume":"72","author":"S Mouly","year":"2002","unstructured":"Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther. 2002;72:1\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"934_CR53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","volume":"15","author":"C Marzolini","year":"2001","unstructured":"Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71\u20135.","journal-title":"AIDS."},{"key":"934_CR54","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAI.0000000000002056","volume":"81","author":"M Johnson","year":"2019","unstructured":"Johnson M, Kumar P, Molina J-M, Rizzardini G, Cahn P, Bickel M, et al. Switching to doravirine\/lamivudine\/tenofovir disoproxil fumarate (DOR\/3TC\/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr. 2019;81:463\u201372.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"934_CR55","doi-asserted-by":"crossref","first-page":"e01298","DOI":"10.1128\/AAC.01298-19","volume":"63","author":"W Greaves","year":"2019","unstructured":"Greaves W, Wan H, Yee KL, Kandala B, Vaddady P, Hwang C. Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine\/lamivudine\/tenofovir disoproxil fumarate. Antimicrob Agents Chemother. 2019. 63:e01298\u201319.","journal-title":"Antimicrob Agents Chemother."},{"key":"934_CR56","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. VIRAMUNE\u00ae (nevirapine) prescribing information. 2018. https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Viramune\/Viramune.pdf. Accessed 23 Oct 2018."},{"key":"934_CR57","doi-asserted-by":"crossref","first-page":"18422","DOI":"10.1073\/pnas.1010693107","volume":"107","author":"IF Sevrioukova","year":"2010","unstructured":"Sevrioukova IF, Poulos TL. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci USA. 2010;107:18422\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"934_CR58","unstructured":"Gilead Sciences, Inc. TYBOST\u00ae (cobicistat) prescribing information. 2018. http:\/\/www.gilead.com\/~\/media\/files\/pdfs\/medicines\/hiv\/tybost\/tybost_pi.pdf. Accessed 23 Oct 2018."},{"key":"934_CR59","unstructured":"University of Washington. Drug Interaction Database Program. 2018. https:\/\/www.druginteractioninfo.org\/. Accessed 20 Jan 2020."},{"key":"934_CR60","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/jac\/dkz224","volume":"74","author":"C Katlama","year":"2019","unstructured":"Katlama C, Assoumou L, Valantin MA, Souli\u00e9 C, Martinez E, B\u00e9niguel L, et al. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96\u00a0weeks in long-term experienced HIV-infected individuals over 45\u00a0years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. J Antimicrob Chemother. 2019;74:2742\u201351.","journal-title":"J Antimicrob Chemother"},{"key":"934_CR61","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","volume":"41","author":"MJ Reese","year":"2013","unstructured":"Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41:353\u201361.","journal-title":"Drug Metab Dispos"},{"key":"934_CR62","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1128\/AAC.00842-09","volume":"54","author":"S Min","year":"2010","unstructured":"Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, et al. Pharmacokinetics and safety of S\/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54:254\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"934_CR63","unstructured":"Merck Sharp & Dohme Corp. ZEPATIER\u00ae (elbasvir\/grazoprevir) prescribing information. Merck & Co., Inc., Whitehouse Station, NJ, USA. 2017. http:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_pi.pdf. Accessed 24 May 2019."},{"key":"934_CR64","unstructured":"Gilead Sciences, Inc. HARVONI\u00ae (ledipasvir\/sofosbuvir) prescribing information. 2017. http:\/\/www.gilead.com\/~\/media\/files\/pdfs\/medicines\/liver-disease\/harvoni\/harvoni_pi.pdf. Accessed 24 May 2019."},{"key":"934_CR65","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1124\/dmd.117.079038","volume":"46","author":"KL Garrison","year":"2018","unstructured":"Garrison KL, German P, Mogalian E, Mathias A. The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection. Drug Metab Dispos. 2018;46:1212\u201325.","journal-title":"Drug Metab Dispos"},{"key":"934_CR66","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1473-3099(17)30303-1","volume":"17","author":"AH Limper","year":"2017","unstructured":"Limper AH, Adenis A, Le T, Harrison TS. Fungal infections in HIV\/AIDS. Lancet Infect Dis. 2017;17:e334\u201343.","journal-title":"Lancet Infect Dis."},{"key":"934_CR67","doi-asserted-by":"crossref","first-page":"6699","DOI":"10.1158\/1078-0432.CCR-05-0703","volume":"11","author":"WP Yong","year":"2005","unstructured":"Yong WP, Ramirez J, Innocenti F, Ratain MJ. Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin Cancer Res. 2005;11:6699\u2013704.","journal-title":"Clin Cancer Res"},{"key":"934_CR68","unstructured":"Janssen Pharmaceuticals. NIZORAL (ketoconazole) prescribing information. 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018533s040lbl.pdf. Accessed 3 Sep 2018."},{"key":"934_CR69","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","volume":"46","author":"EJ Wang","year":"2002","unstructured":"Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother. 2002;46:160\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"934_CR70","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","volume":"45","author":"R Bellmann","year":"2017","unstructured":"Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45:737\u201379.","journal-title":"Infection"},{"key":"934_CR71","unstructured":"World Health Organization. Global tuberculosis report 2017. Geneva, Switzerland; 2017. http:\/\/www.who.int\/tb\/publications\/global_report\/en\/. Accessed 20 Jan 2020."},{"key":"934_CR72","unstructured":"Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2018. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adult_oi.pdf. Accessed 10 Sep 2018."},{"key":"934_CR73","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1128\/AAC.01124-13","volume":"57","author":"B Williamson","year":"2013","unstructured":"Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother. 2013;57:6366\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"934_CR74","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40261-017-0513-4","volume":"37","author":"KL Yee","year":"2017","unstructured":"Yee KL, Khalilieh SG, Sanchez RI, Liu R, Anderson MS, Manthos H, et al. The effect of single and multiple doses of rifampin on the pharmacokinetics of doravirine in healthy subjects. Clin Drug Investig. 2017;37:659\u201367.","journal-title":"Clin Drug Investig."},{"key":"934_CR75","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/jcph.1103","volume":"58","author":"SG Khalilieh","year":"2018","unstructured":"Khalilieh SG, Yee KL, Sanchez RI, Liu R, Fan L, Martell M, et al. Multiple doses of rifabutin reduce exposure of doravirine in healthy subjects. J Clin Pharmacol. 2018;58:1044\u201352.","journal-title":"J Clin Pharmacol"},{"key":"934_CR76","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.apsb.2016.07.014","volume":"6","author":"P Wang","year":"2016","unstructured":"Wang P, Pradhan K, Zhong XB, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B. 2016;6:384\u201392.","journal-title":"Acta Pharm Sin B."},{"key":"934_CR77","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1254\/jphs.FP0040296","volume":"96","author":"Y Nishimura","year":"2004","unstructured":"Nishimura Y, Kurata N, Sakurai E, Yasuhara H. Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci. 2004;96:293\u2013300.","journal-title":"J Pharmacol Sci."},{"key":"934_CR78","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.toxlet.2014.06.006","volume":"229","author":"SY Lee","year":"2014","unstructured":"Lee SY, Jang H, Lee JY, Kwon KI, Oh SJ, Kim SK. Inhibition of cytochrome P450 by ethambutol in human liver microsomes. Toxicol Lett. 2014;229:33\u201340.","journal-title":"Toxicol Lett"},{"issue":"41","key":"934_CR79","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc18-S008","volume":"2018","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142018. Diabetes Care. 2018;2018(41):S73\u201385.","journal-title":"Diabetes Care."},{"key":"934_CR80","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/FPC.0b013e3283559b22","volume":"22","author":"L Gong","year":"2012","unstructured":"Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012;22:820\u20137.","journal-title":"Pharmacogenet Genomics"},{"key":"934_CR81","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","volume":"50","author":"GG Graham","year":"2011","unstructured":"Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50:81\u201398.","journal-title":"Clin Pharmacokinet"},{"key":"934_CR82","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2042018816638050","volume":"7","author":"M May","year":"2016","unstructured":"May M, Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016;7:69\u201383.","journal-title":"Ther Adv Endocrinol Metab."},{"key":"934_CR83","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1124\/dmd.31.9.1090","volume":"31","author":"KA Kim","year":"2003","unstructured":"Kim KA, Park JY. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes. Drug Metab Dispos. 2003;31:1090\u20132.","journal-title":"Drug Metab Dispos"},{"key":"934_CR84","unstructured":"Merck Sharp & Dohme Corp. JANUVIA\u00ae (sitagliptin) prescribing information. 2018. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/j\/januvia\/januvia_pi.pdf. Accessed 24 Oct 2018."},{"key":"934_CR85","unstructured":"AstraZeneca. ONGLYZA\u00ae (saxagliptin) prescribing information. 2018. https:\/\/www.azpicentral.com\/onglyza\/pi_onglyza.pdf. Accessed 23 Oct 2018."},{"key":"934_CR86","unstructured":"Novo Nordisk. VICTOZA\u00ae (liraglutide) prescribing information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/022341s027lbl.pdf. Accessed 24 Oct 2018."},{"key":"934_CR87","first-page":"1","volume":"7","author":"NE Husain","year":"2014","unstructured":"Husain NE, Ahmed MH. Managing dyslipidemia in HIV\/AIDS patients: challenges and solutions. HIV AIDS (Auckl). 2014;7:1\u201310.","journal-title":"HIV AIDS (Auckl)."},{"key":"934_CR88","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF03190074","volume":"25","author":"LR Whitfield","year":"2000","unstructured":"Whitfield LR, Stern RH, Sedman AJ, Abel R, Gibson DM. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase. Eur J Drug Metab Pharmacokinet. 2000;25:97\u2013101.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"934_CR89","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/j.1552-4604.1996.tb04224.x","volume":"36","author":"DD Cilla Jr","year":"1996","unstructured":"Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol. 1996;36:604\u20139.","journal-title":"J Clin Pharmacol"},{"key":"934_CR90","unstructured":"Merck Sharp & Dohme Corp. ZOCOR (simvastatin) prescribing information. 2018. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zocor\/zocor_pi.pdf. Accessed 24 Oct 2018."},{"key":"934_CR91","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11095-006-9159-2","volume":"24","author":"KT Kivist\u00f6","year":"2007","unstructured":"Kivist\u00f6 KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res. 2007;24:239\u201347.","journal-title":"Pharm Res"},{"key":"934_CR92","unstructured":"AstraZeneca. CRESTOR (rosuvastatin calcium) prescribing information. 2018. https:\/\/www.azpicentral.com\/crestor\/crestor.pdf. Accessed 11 Apr 2019."},{"key":"934_CR93","unstructured":"Merck Sharp & Dohme Corp. MEVACOR (lovastatin) prescribing information. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019643s085lbl.pdf. Accessed 11 Apr 2019."},{"key":"934_CR94","unstructured":"Novartis Pharmaceuticals Corporation. Lescol\u00ae (fluvastatin sodium) prescribing information. 2017. https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/Lescol.pdf. Accessed 11 Apr 2019."},{"key":"934_CR95","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12377","volume":"78","author":"T Prueksaritanont","year":"2014","unstructured":"Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, et al. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Br J Clin Pharmacol. 2014;78:587\u201398.","journal-title":"Br J Clin Pharmacol"},{"key":"934_CR96","unstructured":"Kowa Pharmaceuticals America Inc. LIVALO\u00ae (pitavastatin) prescribing information. 2016. https:\/\/www.kowapharma.com\/documents\/LIVALO_PI_CURRENT.pdf. Accessed 11 Apr 2019."},{"key":"934_CR97","unstructured":"Centers for Disease Control and Prevention (CDC). HIV Surveillance Report-Diagnoses of HIV Infection in the United States and Dependent Areas, 2016. 2016. https:\/\/www.cdc.gov\/hiv\/pdf\/library\/reports\/surveillance\/cdc-hiv-surveillance-report-2016-vol-28.pdf. Accessed 23 Jan 2019."},{"key":"934_CR98","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2105\/AJPH.2012.301162","volume":"103","author":"MJ Mimiaga","year":"2013","unstructured":"Mimiaga MJ, Reisner SL, Grasso C, Crane HM, Safren SA, Kitahata MM, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. Am J Public Health. 2013;103:1457\u201367.","journal-title":"Am J Public Health"},{"key":"934_CR99","unstructured":"American Society of Addiction Medicine (ASAM). The ASAM national practice guideline for the use of medications in the treatment of addiction involving opioid use. 2015. https:\/\/www.asam.org\/docs\/default-source\/practice-support\/guidelines-and-consensus-docs\/asam-national-practice-guideline-supplement.pdf. Accessed 23 Jan 2019."},{"key":"934_CR100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1300\/J069v19n01_07","volume":"19","author":"MD Stein","year":"2000","unstructured":"Stein MD, Urdaneta ME, Clarke J, Maksad J, Sobota M, Hanna L, et al. Use of antiretroviral therapies by HIV-infected persons receiving methadone maintenance. J Addict Dis. 2000;19:85\u201394.","journal-title":"J Addict Dis"},{"key":"934_CR101","unstructured":"Indivior Inc. SUBOXONE\u00ae (buprenorphine and naloxone) prescribing information. 2018. https:\/\/www.suboxone.com\/content\/pdfs\/prescribing-information.pdf. Accessed 24 October 2018."},{"key":"934_CR102","unstructured":"Teva Pharmaceuticals. NORDETTE\u00ae-28 prescribing information. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018782s036lbl.pdf. Accessed 24 May 2019."},{"key":"934_CR103","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1124\/dmd.104.000182","volume":"32","author":"B Wang","year":"2004","unstructured":"Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 \u03b1-ethinylestradiol. Drug Metab Dispos. 2004;32:1209\u201312.","journal-title":"Drug Metab Dispos"},{"key":"934_CR104","first-page":"570","volume":"32","author":"I Moreno","year":"2012","unstructured":"Moreno I, Quinones L, Catalan J, Miranda C, Roco A, Sasso J, et al. Influence of CYP3A4\/5 polymorphisms in the pharmacokinetics of levonorgestrel: a pilot study. Biomedica. 2012;32:570\u20137.","journal-title":"Biomedica."},{"key":"934_CR105","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1468-1293.2007.00456.x","volume":"8","author":"J van Lunzen","year":"2007","unstructured":"van Lunzen J, Liess H, Arast\u00e9h K, Walli R, Daut B, Sch\u00fcrmann D. Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy. HIV Med. 2007;8:220\u20135.","journal-title":"HIV Med."},{"key":"934_CR106","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s13318-018-0497-3","volume":"43","author":"KJ Wilby","year":"2018","unstructured":"Wilby KJ, Elssa NA. Clinical pharmacokinetics and drug interactions of doravirine. Eur J Drug Metab Pharmacokinet. 2018;43:637\u201344.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"934_CR107","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s40262-019-00806-9","volume":"58","author":"A Boyle","year":"2019","unstructured":"Boyle A, Moss CE, Marzolini C, Khoo S. Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of doravirine. Clin Pharmacokinet. 2019;58:1553\u201365.","journal-title":"Clin Pharmacokinet"},{"key":"934_CR108","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1128\/AAC.48.6.2091-2096.2004","volume":"48","author":"AM Taburet","year":"2004","unstructured":"Taburet AM, Piketty C, Chazallon C, Vincent I, Gerard L, Calvez V, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48:2091\u20136.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00934-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00934-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00934-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T04:16:16Z","timestamp":1667967376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00934-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":108,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00934-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"20 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Medical writing assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SK, KLY, RS, SAS, LW, and MI are current employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and may own stock and\/or hold stock options in the Merck & Co., Inc., Kenilworth, NJ, USA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/competing interests"}}]}}